Review Article
Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia
Nancy M. Nix, PharmD, BCPS, BCOP, and Allyson Price, MPAS, PA-C
Ballad Health, Johnson City, Tennessee, and MD Anderson Cancer Center, Houston, Texas
Authors’ disclosures of conflicts of interest are found at the end of this article.
Allyson Price, MPAS, PA-C, 1515 Holcombe Boulevard, Houston, TX 77030. E-mail: adprice@mdanderson.org
J Adv Pract Oncol 2019;10(suppl 4):9–18 |
https://doi.org/10.6004/jadpro.2019.10.8.13 |
© 2019 Harborside™
ABSTRACT
Abstract
Until recently, treatment advances in acute myeloid leukemia (AML) had been slow since the 1970s. However, in the past few years, as the understanding of the pathophysiology of AML has advanced, numerous treatments have been approved by the U.S. Food & Drug Administration. This article reviews the mechanisms of action, indications, and clinical trial details for eight novel agents, as well as the current discussions surrounding monitoring minimal residual disease.
This article is a part of a JADPRO certified supplement, Optimizing Treatment and Improving Outcomes for Patients With Acute Myeloid Leukemia: A Guide for Advanced Practitioners
Table of Contents
- Acute Myeloid Leukemia: An Ever-Changing Disease
- Optimizing Use of Newly Approved Agents for Acute Myeloid Leukemia (current article)
- The Role of the Advanced Practitioner in Enhancing Outcomes
- Appendix: Key Information on Newly Approved AML Drugs
For access to the full length article, please
sign in.
